AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17684525 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 500 mg calcium (Ca group)
Number of subjects: 102
Study 15817918 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 15817918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12028741 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/day)
Number of subjects: 109
Study 12028741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 10696277 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stimulus A (1,000 points) vs Negative stimulus B (0 points)
Number of subjects: 0
Study 10696277 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stimulus C (100 points) vs Negative stimulus D (0 points)
Number of subjects: 0
Study 10696277 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stimuli A (1,000 points) vs C (0 points)
Number of subjects: 0
Study 10696277 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stimulus B (1,000 points) vs Negative stimulus D (0 points)
Number of subjects: 0
Study 8935235 — intervention group
Group type: EXPERIMENTAL
Intervention: TS (Tourette syndrome)
Number of subjects: 0
Study 8935235 — intervention group
Group type: EXPERIMENTAL
Intervention: TS/information
Number of subjects: 0
Study 8935235 — intervention group
Group type: COMPARATOR
Intervention: No TS
Number of subjects: 0
Study 1936066 — intervention group
Group type: EXPERIMENTAL
Intervention: Eterobarbital (DMMP) 400 mg
Number of subjects: 8
Study 1936066 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital (PB) 200 mg
Number of subjects: 8
Study 7022286 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213 (etoposide) administered orally at 150 mg/m2/day for 5 days every 3 weeks
Number of subjects: 30
Study 7022286 — intervention group
Group type: COMPARATOR
Intervention: VP-16-213 (etoposide) administered intravenously at 150 mg/m2 weekly
Number of subjects: 30
Study 30584047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-testing plus routine door-to-door HIV testing services
Number of subjects: 26973
Study 30584047 — intervention group
Group type: COMPARATOR
Intervention: PopART standard of care of door-to-door HIV testing services alone
Number of subjects: 26973
Study 30584047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-testing plus routine door-to-door HIV testing services (among men)
Number of subjects: 26973
Study 30584047 — intervention group
Group type: COMPARATOR
Intervention: PopART standard of care of door-to-door HIV testing services alone (among men)
Number of subjects: 26973
Study 29031084 — intervention group
Group type: EXPERIMENTAL
Intervention: Active training
Number of subjects: 76
Study 29031084 — intervention group
Group type: COMPARATOR
Intervention: Random-feedback-based training (Control)
Number of subjects: 76
Study 26293044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac‐QD (tacrolimus once daily)
Number of subjects: 125
Study 23949097 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ratio drink
Number of subjects: 12
Study 23949097 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 ratio drink
Number of subjects: 12
Study 23949097 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 ratio drink
Number of subjects: 12
Study 21821622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive low-energy diet (LED) with dietary consultations, 810 kcal/day during weeks 0-8 and weeks 32-36.
Number of subjects: 89
Study 21821622 — intervention group
Group type: COMPARATOR
Intervention: Minimal attention control group with dietary instruction for 2 hours at baseline, weeks 8, 32, 36, and 52.
Number of subjects: 89
Study 21821622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive low-energy diet (LED) with dietary consultations.
Number of subjects: 89
Study 21821622 — intervention group
Group type: COMPARATOR
Intervention: Minimal attention control group.
Number of subjects: 89
Study 19283866 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic Resonance Vibration (SRV)
Number of subjects: 0
Study 19283866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal Vibration (SV)
Number of subjects: 0
Study 19283866 — intervention group
Group type: COMPARATOR
Intervention: Maximum Voluntary Contraction
Number of subjects: 0
Study 17713431 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 49
Study 17713431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 15075539 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week treatment interruption followed by a six to nine-drug rescue regimen
Number of subjects: 68
Study 15075539 — intervention group
Group type: COMPARATOR
Intervention: Multidrug therapy alone
Number of subjects: 68
Study 11838566 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 50
Study 11838566 — intervention group
Group type: COMPARATOR
Intervention: Nebulized salbutamol
Number of subjects: 50
Study 9483586 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1% ophthalmic solution (LOS)
Number of subjects: 28
Study 9483586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7831455 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (neuroleptic treatment)
Number of subjects: 19
Study 7831455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3417462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 16
Study 3417462 — intervention group
Group type: COMPARATOR
Intervention: Intermittent doses of buprenorphine hydrochloride (0.3 mg intramuscularly every 3 to 6 hours)
Number of subjects: 16
Study 30957909 — intervention group
Group type: EXPERIMENTAL
Intervention: Kognito At Risk for College Students
Number of subjects: 0
Study 30957909 — intervention group
Group type: COMPARATOR
Intervention: Untrained students
Number of subjects: 0
Study 28687626 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 65
Study 28687626 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 65
Study 28687626 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone to Methylprednisolone (crossover phase)
Number of subjects: 65
Study 28687626 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone to Dexamethasone (crossover phase)
Number of subjects: 65
Study 25222881 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg and Glycopyrronium 50 μg (combination)
Number of subjects: 0
Study 25222881 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 150 μg
Number of subjects: 0
Study 25222881 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium 50 μg
Number of subjects: 0
Study 23886280 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Resilience and Enrichment Programme (PREP), six weekly sessions focused on emotional awareness, expression and management, identifying roles and personal strengths, and effective problem-solving skills.
Number of subjects: 132
Study 23886280 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 132
Study 20332355 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated glucagon plus insulin delivery
Number of subjects: 13
Study 20332355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-gain glucagon delivery
Number of subjects: 13
Study 20332355 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-gain glucagon delivery
Number of subjects: 13
Study 20332355 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus insulin
Number of subjects: 13
Study 18836798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with gemcitabine
Number of subjects: 0
Study 18836798 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy followed by chemotherapy
Number of subjects: 0
Study 18836798 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 16278081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral mandibular repositioner appliances (IOMRAs)
Number of subjects: 40
Study 16278081 — intervention group
Group type: COMPARATOR
Intervention: Control Group (improved patients)
Number of subjects: 40
Study 12716689 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus 10,000 U vitamin D(2)/wk
Number of subjects: 187
Study 12716689 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplements alone (1000 mg Ca/d)
Number of subjects: 187
Study 11028551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative enteral immunonutrition (treatment group, n = 102)
Number of subjects: 206
Study 11028551 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral diet (control group, n = 104)
Number of subjects: 206
Study 8681013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear cardiology procedures
Number of subjects: 0
Study 8681013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost effectiveness evaluation
Number of subjects: 0
Study 8681013 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical methods for evaluating diagnostic tests
Number of subjects: 0
Study 1574976 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine infusion
Number of subjects: 10
Study 3897895 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam (2 X 400 mg capsules t.i.d.)
Number of subjects: 40
Study 3897895 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 40
Study 3897895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31891136 — intervention group
Group type: EXPERIMENTAL
Intervention: BLTR (Bilamellar Tarsal Rotation)
Number of subjects: 1000
Study 31891136 — intervention group
Group type: EXPERIMENTAL
Intervention: PLTR (Posterior Lamellar Tarsal Rotation)
Number of subjects: 1000
Study 29576369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet + exercise
Number of subjects: 277
Study 29576369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet
Number of subjects: 277
Study 29576369 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 277
Study 29576369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic-fat loss
Number of subjects: 277
Study 26303808 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 100
Study 26303808 — intervention group
Group type: COMPARATOR
Intervention: Routine care (incubator care)
Number of subjects: 100
Study 25077916 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified anthocyanins (320 mg/day)
Number of subjects: 150
Study 25077916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 22889987 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training + whey supplement (RW)
Number of subjects: 30
Study 22889987 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training + placebo (RP)
Number of subjects: 30
Study 22889987 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study 19535219 — intervention group
Group type: EXPERIMENTAL
Intervention: Large particle-size hyaluronic acid (LPHA)
Number of subjects: 17
Study 19535219 — intervention group
Group type: COMPARATOR
Intervention: Small particle-size hyaluronic acid (SPHA)
Number of subjects: 17
Study 17442904 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin threshold of 7 g per deciliter)
Number of subjects: 637
Study 17442904 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin threshold of 9.5 g per deciliter)
Number of subjects: 637
Study 17442904 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 637
Study 17442904 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 637
Study 17442904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 637
Study 16181835 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin (60 mg/m2 intravenously) and 5-fluorouracil (1,000 mg/m2 per day) for 4 days, three cycles at 3-week intervals
Number of subjects: 40
Study 16181835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 40
Study 16181835 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 40
Study 12909505 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin, 0.625 mg for 25 days monthly, with Provera, 10 mg for 10 of these 25 days (hormone therapy) for 2 years
Number of subjects: 55
Study 12909505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 10503801 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst-rank score analysis for informatively missing observations
Number of subjects: 0
Study 10503801 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst-rank score analysis
Number of subjects: 0
Study 9012222 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely solution (3 litres)
Number of subjects: 150
Study 9012222 — intervention group
Group type: COMPARATOR
Intervention: Clean Prep (4 litres)
Number of subjects: 150
Study 9012222 — intervention group
Group type: COMPARATOR
Intervention: X-Prep with eating restriction (3 days)
Number of subjects: 150
Study 1871737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-supplemented diet (added to bread, breakfast cereals, porridge, or crispbread)
Number of subjects: 5
Study 1871737 — intervention group
Group type: COMPARATOR
Intervention: Crispbread (control group)
Number of subjects: 5
Study 1871737 — intervention group
Group type: COMPARATOR
Intervention: Control groups (three groups)
Number of subjects: 5
Study 6349668 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg once daily for 4 weeks
Number of subjects: 0
Study 6349668 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily for 4 weeks
Number of subjects: 0
Study 6349668 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily for 4 weeks
Number of subjects: 0
Study 6349668 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (all doses)
Number of subjects: 0
Study 30654534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (4 sessions)
Number of subjects: 0
Study 30654534 — intervention group
Group type: COMPARATOR
Intervention: Mindlessness group (control)
Number of subjects: 0
Study 30322501 — intervention group
Group type: EXPERIMENTAL
Intervention: Early drain removal (drains removed output‐based, i.e., flow less than 30 ml/day)
Number of subjects: 99
Study 30322501 — intervention group
Group type: COMPARATOR
Intervention: Control group (drains removed at hospital discharge, i.e., 4-5 days after surgery)
Number of subjects: 99
Study 26919568 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.2% in 8% low‐molecular weight dextran
Number of subjects: 54
Study 26919568 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.2% in saline (control)
Number of subjects: 54
Study 24574507 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential spread of local anaesthetic (LA)
Number of subjects: 21
Study 24574507 — intervention group
Group type: COMPARATOR
Intervention: Non-circumferential spread of local anaesthetic (LA)
Number of subjects: 21
Study 24574507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (circumferential and non-circumferential)
Number of subjects: 21
Study 22251130 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine (6 g)
Number of subjects: 15
Study 22251130 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 21062666 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 5425
Study 21062666 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 5425
Study 17397305 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrate (PC)
Number of subjects: 20
Study 15086925 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g per day
Number of subjects: 34
Study 15086925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12066638 — intervention group
Group type: EXPERIMENTAL
Intervention: CerAdapt (test) abutments after 1 year
Number of subjects: 69
Study 12066638 — intervention group
Group type: COMPARATOR
Intervention: CeraOne (control) abutments after 1 year
Number of subjects: 69
Study 12066638 — intervention group
Group type: EXPERIMENTAL
Intervention: CerAdapt (test) and CeraOne (control) abutments between 1 and 3 years
Number of subjects: 69
Study 12066638 — intervention group
Group type: EXPERIMENTAL
Intervention: CerAdapt (test) and CeraOne (control) abutments
Number of subjects: 69
Study 9824172 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape of initial interview (experimental group)
Number of subjects: 18
Study 9824172 — intervention group
Group type: COMPARATOR
Intervention: Placebo videotape (control group)
Number of subjects: 18
Study 8110696 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol 0.1 mg
Number of subjects: 0
Study 8110696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual timolol 0.1 mg
Number of subjects: 0
Study 8110696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (topical)
Number of subjects: 0
Study 2483239 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy
Number of subjects: 3
Study 2483239 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drugs
Number of subjects: 3
Study 19189 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic bronchodilator
Number of subjects: 0
Study 19189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19189 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-adrenergic therapy
Number of subjects: 0
Study 31911130 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanxi Dayi Hospital score (SDH score)
Number of subjects: 776
Study 31911130 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 776
Study 31911130 — intervention group
Group type: COMPARATOR
Intervention: Wells score
Number of subjects: 776
Study 31911130 — intervention group
Group type: COMPARATOR
Intervention: Revised Geneva score
Number of subjects: 776
Study 31911130 — intervention group
Group type: COMPARATOR
Intervention: Wells score and Revised Geneva score
Number of subjects: 776
Study 31567466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine
Number of subjects: 0
Study 31567466 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose vaccine
Number of subjects: 0
Study 31567466 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 0
Study 31567466 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0
Study 28865902 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate auditory feedback
Number of subjects: 69
Study 28865902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 69
Study 28865902 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed auditory feedback
Number of subjects: 69
Study 28865902 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed visual feedback
Number of subjects: 69
Study 26406293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AMH (<1.00 ng/mL, n = 124)
Number of subjects: 1202
Study 26406293 — intervention group
Group type: COMPARATOR
Intervention: Normal AMH (1.00-3.5 ng/mL, n = 595)
Number of subjects: 1202
Study 26406293 — intervention group
Group type: EXPERIMENTAL
Intervention: High AMH (>3.5 ng/mL, n = 483)
Number of subjects: 1202
Study 23791606 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral nerve block for routine dental procedures
Number of subjects: 0
Study 23791606 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic cream
Number of subjects: 0
Study 21540233 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels (fifth compared with first quintile)
Number of subjects: 255
Study 21540233 — intervention group
Group type: EXPERIMENTAL
Intervention: CML-AGE levels (fifth compared with first quintile)
Number of subjects: 255
Study 18521616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearing high flex TKA
Number of subjects: 60
Study 18521616 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearing posterior stabilized TKA
Number of subjects: 60
Study 18521616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16961168 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (180 - 2160 mg)
Number of subjects: 0
Study 16961168 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (not specified dosage)
Number of subjects: 0
Study 15666026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosonography
Number of subjects: 50
Study 11759868 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental fixture placed in a fresh extraction socket (TI)
Number of subjects: 48
Study 11759868 — intervention group
Group type: COMPARATOR
Intervention: Contralateral fixture in mature bone (CI)
Number of subjects: 48
Study 15625835 — intervention group
Group type: EXPERIMENTAL
Intervention: Holothuria Ldeucospilota Acidic Mucopolysaccharide (HLAM) 60 mg/d
Number of subjects: 0
Study 15625835 — intervention group
Group type: EXPERIMENTAL
Intervention: Holothuria Ldeucospilota Acidic Mucopolysaccharide (HLAM) 120 mg/d
Number of subjects: 0
Study 8116326 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 8116326 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 40
Study 3320844 — intervention group
Group type: EXPERIMENTAL
Intervention: Periapical instrumentation
Number of subjects: 106
Study 3320844 — intervention group
Group type: COMPARATOR
Intervention: Intracanal instrumentation
Number of subjects: 106
Study 31172211 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral hypervascularity of the corpus luteum on ultrasound (Doppler US)
Number of subjects: 69
Study 31172211 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral hypervascularity of the corpus luteum on CT (CECT)
Number of subjects: 69
Study 31172211 — intervention group
Group type: COMPARATOR
Intervention: No peripheral hypervascularity of the corpus luteum
Number of subjects: 69
Study 31172211 — intervention group
Group type: COMPARATOR
Intervention: Size of torsed ovaries
Number of subjects: 69